44 2033180199

Hereditary profiling of CLL: a 'TP53 fiend' opinion

Kritika Kundaliya

Chronic Lymphocytic Leukemia (CLL) is a B-cell danger with an exceptionally factor clinical course. While a few patients require treatment moderately before long determination, others may stay liberated from side effects for a long time with a standard ‘observe furthermore, stand by’ reconnaissance approach.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。
 
协会、社团和大学的同行评审出版 pulsus-health-tech
Top